Achieve Life Sciences Awarded FDA National Priority Voucher for Cytisinicline to Aid in E-cigarette and Vaping Cessation Efforts

FDA Expedited Review for Cytisinicline: Achieve Life Sciences has received a Commissioner’s National Priority Voucher from the FDA for cytisinicline, a potential first-in-class treatment for nicotine dependence specifically aimed at e-cigarette and vaping cessation, allowing for an expedited review process.

Clinical Efficacy and Future Trials: Cytisinicline has shown promising results in clinical trials, being 2.6 times more effective than placebo in helping users quit vaping, and the FDA has granted it Breakthrough Therapy designation, with plans for a Phase 3 trial to support its New Drug Application.